Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

244

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: GSK1265744 10 mg
DRUG: GSK1265744 30 mg
DRUG: GSK1265744 60 mg
DRUG: Efavirenz 600 mg
DRUG: Rilpivirine 25 mg
DRUG: Placebo
DRUG: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)

Sponsor

ViiV Healthcare

Collaborators

[object Object]